Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women | NEJM

Long-acting injectable cabotegravir (CAB-LA) given intramuscularly every 8 weeks was superior to daily oral TDF–FTC in preventing HIV infection among MSM and transgender women. Kudos for including transgender women in this study!

Read the full article here

Related Articles